Bastide le Confort Medical S.A.

Bastide le Confort Medical is a holding company. Through its subsidiaries, Co. is engaged in the home health care industry. Co. retails and rents medical equipment and provides medical services. Products include breathing apparatus, orthopedic shoes, walking aids and wheelchairs, home appliances and furniture adapted to the needs of the lesser able, with the recent addition of equipment related to perfusion and nutrition. Co. operates through a number of outlets concentrated mainly in the South of France, offering advice and information to customers along with the provision and maintenance of medical equipment.
  • TickerBLC
  • ISINFR0000035370
  • ExchangeEuronext Paris
  • SectorHealth Care Equipment & Services
  • CountryFrance

Analysts

Ahmed Ben Salem ...
  • Baptiste Lebacq
  • Charles Lepetitpas
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Nicolas David
  • Salma Bouraoui
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 11/15/2018

...

Ahmed Ben Salem ...
  • Baptiste Lebacq
  • Charles Lepetitpas
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Nicolas David
  • Salma Bouraoui
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 15/11/2018

...

Christophe-Raphaël Ganet

Bastide : Good Q1 2018-19 – Confidence regarding guidance

>Q1 2018-19: +28.6%, incl. +6.4% organic. - Q1 sales totalled € 79.4m, up +28.6%, of which +6.4% organic.Bastide confirmed its 2018 guidance.In line with the guidance - This Q1 sales data topped our expectations: i/ we had overestimated the price impact on the PNI division and probably the scope effects slightly, ii/ the contribution from Baywater beat our estimates (€ 7.4m vs € 7m est.), ii/ in respiratory assistance, Bastide continues to win m...

Christophe-Raphaël Ganet

Bastide : Bon T1 2018-2019 – Confiance vis-à-vis des guidances

>T1 2018-19 : +28.6% dont +6.4% organique - Le CA T1 s'élève à 79.4 M€, +28.6% dont +6.4% organique.Bastide confirme ses guidances pour 2018-19.En ligne avec les guidances - Ce CA T1 se situe au-dessus de nos attentes : i/ nous avions surestimé l’impact tarifaire sur la division PNI et sans doute un peu les effets périmètres, ii/ la contribution de Baywater ressort au-dessus de nos attentes (7.4 M€ vs 7 M€e), ii/ en ARD, Bastide continue de gagn...

1 director bought

A director at Bastide Le Confort Medical bought 29,000 shares at 34.500EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The...

Christophe-Raphaël Ganet

Bastide : Good Q1 2018-19 – Confidence regarding guidance

>Q1 2018-19: +28.6%, incl. +6.4% organic. - Q1 sales totalled € 79.4m, up +28.6%, of which +6.4% organic.Bastide confirmed its 2018 guidance.In line with the guidance - This Q1 sales data topped our expectations: i/ we had overestimated the price impact on the PNI division and probably the scope effects slightly, ii/ the contribution from Baywater beat our estimates (€ 7.4m vs € 7m est.), ii/ in respiratory assistance, Bastide continues to win m...

Christophe-Raphaël Ganet

Bastide : Bon T1 2018-2019 – Confiance vis-à-vis des guidances

>T1 2018-19 : +28.6% dont +6.4% organique - Le CA T1 s'élève à 79.4 M€, +28.6% dont +6.4% organique.Bastide confirme ses guidances pour 2018-19.En ligne avec les guidances - Ce CA T1 se situe au-dessus de nos attentes : i/ nous avions surestimé l’impact tarifaire sur la division PNI et sans doute un peu les effets périmètres, ii/ la contribution de Baywater ressort au-dessus de nos attentes (7.4 M€ vs 7 M€e), ii/ en ARD, Bastide continue de gagn...

Christophe-Raphaël Ganet

ODDO : Q3 2018 previews: expensive healthcare

>T3: +9.7%e forecast - After growth of around +10% in H1, our forecasts are for growth in the region of 9.7% in Q3.Growth levels are fairly disparate but we can say that the most robust growth levels will likely come from Ipsen, Sartorius Stedim Biotech and bioMérieux. The weakest growth levels will probably be generated by Guerbet, Boiron and Vétoquinol.Virbac has already reported its Q3 results, these were towards the upper end of the forecast range. Q3 pu...

Christophe-Raphaël Ganet

ODDO : Previews T3 2018: chère Santé

>T3: +9.7%e attendus - Après un CA S1 ressortant à environ +10%, nos projections tablent sur une croissance de 9.7%e au T3.Les niveaux de croissance sont assez disparates mais on peut dire que les plus fortes croissances organiques proviendront d’Ipsen, Sartorius Stedim Biotech et bioMérieux. Les plus faibles devraient être publiés par Guerbet, Boiron et Vétoquinol.Le T3 de Virbac a déjà été publié, il était plutôt dans le haut de fourchette des attentes. Le...

Christophe-Raphaël Ganet

Bastide : 2017-18 results in line - Excessive drop in share price – TP: € 42 vs € 52 - Buy vs Neutral

>Healthy full- year results, in line with expectations - End-June 2018 EBITDA reached € 54.4m, i.e. +32.5% and 18.8% of revenue. Current operating profit came to € 23.3m, +44% (vs € 23.7m expected), i.e. 8.1% of revenue. These 2017-18 results are in line with our expectations and show that i/ Bastide benefited from mix effects as expected (stronger growth and a contribution from the services activities), particularly as regards external growth, ii/ franchises con...

1 director bought

A director at Bastide Le Confort Medical bought 29,000 shares at 34.500EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The...

Ahmed Ben Salem ...
  • Baptiste Lebacq
  • Charles Lepetitpas
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Nicolas David
  • Salma Bouraoui
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 11/15/2018

...

Ahmed Ben Salem ...
  • Baptiste Lebacq
  • Charles Lepetitpas
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Nicolas David
  • Salma Bouraoui
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 15/11/2018

...

Alex Koagne ...
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Jean Sassus
  • Olfa Taamallah
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 10/15/2018

...

Ahmed Ben Salem ...
  • Bruno Cavalier
  • Christophe-Raphaël Ganet
  • Emira Sagaama
  • Jean Sassus
  • Laure Billoret
  • Matthias Desmarais
  • Steven Gould
  • Valentin Pernet
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/15/2018

...

Ahmed Ben Salem ...
  • Bruno Cavalier
  • Christophe-Raphaël Ganet
  • Emira Sagaama
  • Jean Sassus
  • Laure Billoret
  • Matthias Desmarais
  • Steven Gould
  • Valentin Pernet
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 15/10/2018

...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Charles Pinel

Etude de l'AG du 25/11/2016

Les dépenses non déductibles font l'objet d'une résolution spécifique. Elles ont augmenté très fortement lors des deux derniers exercices pour atteindre un montant de 233 356 € (+51%). Aucune justification n'est apportée par la société sur ce montant élevé ainsi que sur les évolutions entre chaque exercice malgré la demande effectuée par Proxinvest. Par conséquent, la résolution ne sera pas soutenue (résolution 3).Il est proposé aux actionnaires de constater que les conventions réglementées antérieurement conclues ont continué à produire leurs effets au cours de l'exercice écoulé. Parmi celles...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch